Targeting hypoxia in cancer therapy
The DOI matches its Crossref record; 190 of the 190 references it cites were found in a registry or an index.
Abstract
Hypoxia is a feature of most tumours, albeit with variable incidence and severity within a given patient population. It is a negative prognostic and predictive factor owing to its multiple contributions to chemoresistance, radioresistance, angiogenesis, vasculogenesis, invasiveness, metastasis, resistance to cell death, altered metabolism and genomic instability. Given its central role in tumour progression and resistance to therapy, tumour hypoxia might well be considered the best validated target that has yet to be exploited in oncology. However, despite an explosion of information on hypoxia, there are still major questions to be addressed if the long-standing goal of exploiting tumour hypoxia is to be realized. Here, we review the two main approaches, namely bioreductive prodrugs and inhibitors of molecular targets upon which hypoxic cell survival depends. We address the particular challenges and opportunities these overlapping strategies present, and discuss the central importance of emerging diagnostic tools for patient stratification in targeting hypoxia.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Several approaches for targeting hypoxic tumor cells have been proposed including hypoxia-activated prodrugs, gene therapy, recombinant anaerobic bacteria, specific targeting of HIFs, or targeting pathways important in hypoxic cells such as the mTOR and UPR pathways (Melillo, 2007;Wilson & Hay, 2011;Semenza, 2012).”
From Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer (2016) · cites this paper as Wilson & Hay, 2011
In the citing paper
“Endothelial cells, fibroblasts, and immune cells are the three main cell types which appear in most cancers and are vital components in enhancing the drug resistance of tumors [103, 114-120].”
From Microfluidic modelling of the tumor microenvironment for anti-cancer drug development (2019) · cites this paper as [120]
In the citing paper
“Endothelial cells, fibroblasts, and immune cells are the three main cell types which appear in most cancers and are vital components in enhancing the drug resistance of tumors [103, 114-120].”
From Microfluidic modelling of the tumor microenvironment for anti-cancer drug development (2019) · cites this paper as [120]
In the citing paper
“Hypoxic environment, on the other hand, is known to reduce cytotoxicity of many anticancer drugs, affect angiogenesis, promote metastasis and alter the metabolic activity of cancer cells [183,197].”
From Microfluidic modelling of the tumor microenvironment for anti-cancer drug development (2019) · cites this paper as [183]
In the citing paper
“In addition to increasing drug resistance, a high SS could influence tumor cells' gene expression, comprise immune cells ability to kill cancerous cells or even turn macrophages to tumorfriendly cells, thereby enhancing the metastatic potential of cancer cells [180-184].”
From Microfluidic modelling of the tumor microenvironment for anti-cancer drug development (2019) · cites this paper as [183]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Targeting HIF-1 for cancer therapy
Semenza, G. L. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1187 · Cited by 6,717 · cited 1×
“The two main oxygen-responsive signalling pathways that mediate adaptation to hypoxia are centred on the HIF family of transcription factor”
BackgroundNormalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527 · cited 1×
“Initially, hypoxia arises because of oxygen diffusion limitations in avascular primary tumours or their metastases, but the tumour microvasculature (induced in part as a response to this hypoxia) is highly abnorma”
BackgroundNetwork medicine: a network-based approach to human disease
Barabási, A.-L., Gulbahce, N., & Loscalzo, J. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2918 · Cited by 5,034
Regulation of cancer cell metabolism
Cairns, R. A., Harris, I. S., & Mak, T. W. (2011) · Nature Reviews Cancer · doi:10.1038/nrc2981 · Cited by 4,744
Drug penetration in solid tumours
Minchinton, A. I., & Tannock, I. F. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1893 · Cited by 2,805
Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours
Graeber, T. G., Osmanian, C., Jacks, T., Housman, D. E., Koch, C. J., Lowe, S. W., & Giaccia, A. J. (1996) · Nature · doi:10.1038/379088a0 · Cited by 2,300
DNA repair pathways as targets for cancer therapy
Helleday, T., Petermann, E., Lundin, C., Hodgson, B., & Sharma, R. A. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2342 · Cited by 1,666
Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice
Sonveaux, P., Végran, F., Schroeder, T., Wergin, M. C., Verrax, J., Rabbani, Z. N., De Saedeleer, C. J., Kennedy, K. M., Diepart, C., Jordan, B. F., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci36843 · Cited by 1,624
Mitochondrial complex III is required for hypoxia-induced ROS production and cellular oxygen sensing
Guzy, R. D., Hoyos, B., Robin, E., Chen, H., Liu, L., Mansfield, K. D., Simon, M. C., Hammerling, U., & Schumacker, P. T. (2005) · Cell Metabolism · doi:10.1016/j.cmet.2005.05.001 · Cited by 1,545
Brugarolas, J., Lei, K., Hurley, R. L., Manning, B. D., Reiling, J. H., Hafen, E., Witters, L. A., Ellisen, L. W., & Kaelin, W. G. (2004) · Genes & Development · doi:10.1101/gad.1256804 · Cited by 1,384 · cited 1×
“The mechanisms include activation of the tuberous sclerosis 1 (TSC1)–TSC2 complex through the HIF1 target gene DNA-damage-inducible transcript 4 ( DDIT4 ; also known as REDD1”
Background
Cited by
Items 801–900 of 1,015
Diflavin Oxidoreductases Activate the Bioreductive Prodrug PR-104A under Hypoxia
Guise, C. P., Abbattista, M. R., Tipparaju, S. R., Lambie, N., Su, J., Li, D., Wilson, W. R., Dachs, G. U., & Patterson, A. V. (2011) · Molecular Pharmacology · doi:10.1124/mol.111.073759 · Cited by 74
Self-citationToward precision medicine of breast cancer
Carels, N., Spinassé, L. B., Tilli, T. M., & Tuszyński, J. A. (2016) · Theoretical Biology and Medical Modelling · doi:10.1186/s12976-016-0035-4 · Cited by 70
A Highly Sensitive Chemiluminescent Probe for Detecting Nitroreductase and Imaging in Living Animals
Sun, J., Hu, Z., Wang, R., Zhang, S., & Zhang, X. (2018) · Analytical Chemistry · doi:10.1021/acs.analchem.8b03955 · Cited by 66
Current understandings and clinical translation of nanomedicines for breast cancer therapy
Jiang, Y., Jiang, Z., Wang, M., & Ma, L. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.114034 · Cited by 72
Huang, D., Zhao, C., Wen, B., Fu, X., Shang, L., Kong, W., & Zhao, Y. (2022) · Chemical Engineering Journal · doi:10.1016/j.cej.2022.134871 · Cited by 66
Hypoxia-Responsive Host–Guest Drug Delivery System
Hu, X., Fu, R., & Guo, D. (2023) · Accounts of Materials Research · doi:10.1021/accountsmr.3c00130 · Cited by 70
HIF-1α in colorectal carcinoma: review of the literature.
Ιωάννου, Μ., Paraskeva, E., Baxevanidou, K., Simos, G., Papamichali, R., Papacharalambous, C., Σαμαρά, Μ., & Koukoulis, G. Κ. (2015) · PubMed · Cited by 89
Al‐Owais, M. M., Scragg, J. L., Dallas, M. L., Boycott, H. E., Warburton, P., Chakrabarty, A., Boyle, J. P., & Peers, C. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.357012 · Cited by 67
Irshad, K., Mohapatra, S. K., Srivastava, C., Garg, H., Mishra, S., Dikshit, B., Sarkar, C., Gupta, D. K., Chandra, P. S., Chattopadhyay, P., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0118201 · Cited by 73
Bioengineered human tumor within a bone niche
Villasante, A., Marturano-Kruik, A., & Vunjak‐Novakovic, G. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2014.03.081 · Cited by 67
Zhang, L., Takara, K., Yamakawa, D., Kidoya, H., & Takakura, N. (2015) · Cancer Science · doi:10.1111/cas.12836 · Cited by 68
A novel anticancer theranostic pro-prodrug based on hypoxia and photo sequential control
Feng, W., Gao, C., Liu, W., Ren, H., Wang, C., Ge, K., Li, S., Zhou, G., Li, H., Wang, S., et al. (2016) · Chemical Communications · doi:10.1039/c6cc02932a · Cited by 64
Clonal cooperativity in heterogenous cancers
Zhou, H., Neelakantan, D., & Ford, H. L. (2016) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2016.08.028 · Cited by 74
Engineered Breast Cancer Cell Spheroids Reproduce Biologic Properties of Solid Tumors
Ham, S. L., Joshi, R., Luker, G. D., & Tavana, H. (2016) · Advanced Healthcare Materials · doi:10.1002/adhm.201600644 · Cited by 64
DNA Adducts from Anticancer Drugs as Candidate Predictive Markers for Precision Medicine
Stornetta, A., Zimmermann, M., Cimino, G. D., Henderson, P. T., & Sturla, S. J. (2016) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.6b00380 · Cited by 68
Hypoxia driven glycation: Mechanisms and therapeutic opportunities
Khan, M. I., Rath, S., Adhami, V. M., & Mukhtar, H. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.05.008 · Cited by 75
Hypoxia-Responsive 19F MRI Probes with Improved Redox Properties and Biocompatibility
Xie, D., Kim, S., Kohli, V., Banerjee, A., Yu, M., Enriquez, J. S., Luci, J. J., & Que, E. L. (2017) · Inorganic Chemistry · doi:10.1021/acs.inorgchem.7b00500 · Cited by 66
Association of PD-L1 and HIF-1α Coexpression with Poor Prognosis in Hepatocellular Carcinoma
Dai, X., Pi, G., Yang, S., Chen, G. Y., Liu, L., & Dong, H. (2018) · Translational Oncology · doi:10.1016/j.tranon.2018.02.014 · Cited by 70
Kadel, D., Zhang, Y., Sun, H.-R., Zhao, Y., Dong, Q.-Z., & Qin, L.-X. (2019) · Cell Biology and Toxicology · doi:10.1007/s10565-019-09461-z · Cited by 63
Modeling the regulation of p53 activation by HIF‐1 upon hypoxia
Wang, P., Guan, D., Zhang, X., Liu, F., & Wang, W. (2019) · FEBS Letters · doi:10.1002/1873-3468.13525 · Cited by 65
Dual Hypoxia-Targeting RNAi Nanomedicine for Precision Cancer Therapy
Li, Y., Ding, J., Xu, X., Shi, R., Saw, P. E., Wang, J., Chung, S., Li, W., Aljaeid, B. M., Lee, R. J., et al. (2020) · Nano Letters · doi:10.1021/acs.nanolett.0c00757 · Cited by 64
Liu, Z., Zhang, Y., Shen, N., Sun, J., Tang, Z., & Chen, X. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114138 · Cited by 68
Marcucci, F., Bellone, M., Caserta, C. A., & Corti, A. (2013) · International Journal of Cancer · doi:10.1002/ijc.28572 · Cited by 71
SIRT1 Regulates Endothelial Notch Signaling in Lung Cancer
Xie, M., Liu, M., & He, C. (2012) · PLoS ONE · doi:10.1371/journal.pone.0045331 · Cited by 87
McKeage, M. J., Jameson, M. B., Ramanathan, R. K., Rajendran, J. G., Gu, Y., Wilson, W. R., Melink, T. J., & Tchekmedyian, N. S. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-496 · Cited by 63
Self-citationYılmaz, A., Bietenbeck, M., Florian, A. R., Faber, C., & Sechtem, U. P. (2016) · International Journal of Nanomedicine · doi:10.2147/ijn.s110542 · Cited by 72
Tumor hypoxia and reoxygenation: the yin and yang for radiotherapy
Hong, B.-J., Kim, J., Jeong, H., Bok, S., Kim, Y.-E., & Ahn, G.-O. (2016) · Radiation Oncology Journal · doi:10.3857/roj.2016.02012 · Cited by 63
Wang, L., Yin, H., Cui, P., Hetu, M., Wang, C., Monro, S. M. A., Schaller, R. D., Cameron, C. G., Liu, B., KILINA, S. V., et al. (2017) · Dalton Transactions · doi:10.1039/c7dt00913e · Cited by 66
Hypoxia imaging and radiotherapy: bridging the resolution gap
Grimes, D. R., Warren, D., & Warren, S. (2017) · British Journal of Radiology · doi:10.1259/bjr.20160939 · Cited by 74
Oxygen nanobubbles revert hypoxia by methylation programming
Bhandari, P. N., Cui, Y., Elzey, B. D., Goergen, C. J., Long, C. M., & Irudayaraj, J. (2017) · Scientific Reports · doi:10.1038/s41598-017-08988-7 · Cited by 66
Pt nanozyme for O 2 self-sufficient, tumor-specific oxidative damage and drug resistance reversal
Ma, Z., Wu, L. B., Han, K., & Han, H. (2019) · Nanoscale Horizons · doi:10.1039/c9nh00088g · Cited by 63
He, H., Liu, L., Liang, R., Zhou, H., Pan, H., Zhang, S., & Cai, L. (2020) · Acta Biomaterialia · doi:10.1016/j.actbio.2020.01.012 · Cited by 64
Revitalizing T cells: breakthroughs and challenges in overcoming T cell exhaustion
Wu, Y., Wu, Y., Gao, Z., Yu, W., Zhang, L., & Zhou, F. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02327-3 · Cited by 89
Sadri, N., & Zhang, P. J. (2013) · Cancers · doi:10.3390/cancers5020320 · Cited by 67
YAMADA, N., YAMANEGI, K., OHYAMA, H., HATA, M., NAKASHO, K., FUTANI, H., OKAMURA, H., & TERADA, N. (2012) · International Journal of Oncology · doi:10.3892/ijo.2012.1630 · Cited by 62
Hypoxia-Responsive Polypeptide Nanoparticles Loaded with Doxorubicin for Breast Cancer Therapy
Zhang, P., Yang, H., Shen, W. H., Liu, W., Chen, L., & Xiao, C. (2020) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.0c00125 · Cited by 63
Hypoxia, Epithelial-Mesenchymal Transition, and TET-Mediated Epigenetic Changes
Kao, S.-H., Wu, K., & Lee, W. (2016) · Journal of Clinical Medicine · doi:10.3390/jcm5020024 · Cited by 68
Jin, F., Yang, R., Yao, W., Wang, D., Zhu, Y., Wang, X., Lu, Y., Wang, Y., Zen, K., & Li, L. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.10.025 · Cited by 64
Campillo, N., Falcones, B., Otero, J., Colina, R., Gozal, D., Navajas, D., Farré, R., & Almendros, I. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00043 · Cited by 66
Joshi, U., Filipczak, N., Khan, M. M., Attia, S. A., & Torchilin, V. P. (2020) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2020.119915 · Cited by 65
Du, Y., Wei, N., Ma, R., Jiang, S., & Song, D. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.580176 · Cited by 66
Meng, L., Wang, C., Lu, Y., Sheng, G., Yang, L., Wu, Z., Xu, H., Han, C., Lu, Y., & Han, F. (2021) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.1c00347 · Cited by 62
Park, J. Y., Jeong, J. Y., Park, J. Y., Kim, H. J., Park, C. S., Lee, J., Park, H. Y., Jung, J. H., Kim, W. W., Chae, Y. S., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-92283-z · Cited by 72
Gold nanoclusters: Photophysical properties and photocatalytic applications
Cheng, D., Liu, R., & Hu, K. (2022) · Frontiers in Chemistry · doi:10.3389/fchem.2022.958626 · Cited by 69
Guo, H., Zhang, W., Wang, L., Shao, Z., & Huang, X. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121821 · Cited by 63
Magistrato, A., Pavlin, M., Qasem, Z., & Ruthstein, S. (2019) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2019.05.002 · Cited by 64
Shi, J., Wang, H., Feng, W., Huang, S., An, J., Qiu, Y., & Wu, K. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.172615 · Cited by 64
Fluorescence resonance energy transfer-based drug delivery systems for enhanced photodynamic therapy
Huang, Y., Qiu, F., Chen, R., Yan, D., & Zhu, X. (2020) · Journal of Materials Chemistry B · doi:10.1039/d0tb00262c · Cited by 61
Enhanced Anticancer Efficacy by ATP‐Mediated Liposomal Drug Delivery
Mo, R., Jiang, T., & Gu, Z. (2014) · Angewandte Chemie · doi:10.1002/ange.201400268 · Cited by 62
The emerging role of hypoxia-inducible factor-2 involved in chemo/radioresistance in solid tumors
Zhao, J., Du, F., Luo, Y., Shen, G., Zheng, F., & Xu, B. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.05.004 · Cited by 69
Schumacher, O., Galvao, D. A., Taaffe, D. R., Chee, R., Spry, N. A., & Newton, R. U. (2020) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-020-0245-z · Cited by 70
Proof-of-principle for two-stage photodynamic therapy: hypoxia triggered release of singlet oxygen
Ayan, S., Günaydın, G., Yeşilgül, N., Gedik, M. E., Seven, Ö., & Akkaya, E. U. (2020) · Chemical Communications · doi:10.1039/d0cc06031c · Cited by 60
Bashash, D., Zandi, Z., Kashani, B., Pourbagheri‐Sigaroodi, A., Salari, S., & Ghaffari, S. H. (2021) · Journal of Cellular Physiology · doi:10.1002/jcp.30575 · Cited by 65
Applications and enhancement strategies of ROS-based non-invasive therapies in cancer treatment
Guo, Q., Tang, Y., Wang, S., & Xia, X. (2025) · Redox Biology · doi:10.1016/j.redox.2025.103515 · Cited by 67
Kumar, S., Donti, T., Agnihotri, N., & Mehta, K. (2013) · International Journal of Cancer · doi:10.1002/ijc.28623 · Cited by 64
Guo, X., Xue, H., Guo, X., Gao, X. C., Xu, S., Yan, S., Han, X., Li, T., Shen, J., & Li, G. (2015) · Oncotarget · doi:10.18632/oncotarget.5871 · Cited by 61
The unexpected effect of PEGylated gold nanoparticles on the primary function of erythrocytes
He, Z., Liu, J., & Du, L. (2014) · Nanoscale · doi:10.1039/c4nr01857e · Cited by 63
Sun, L., Liu, S., Wang, R., Jiang, Y., Zhang, Y., Zhang, J., Bao, L., Kaltenboeck, L., Dunham, R. A., Waldbieser, G., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0109666 · Cited by 66
Yang, B., Zhang, S., Fang, X., & Kong, J. (2019) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2019.111544 · Cited by 60
Hypoxia‐Targeted siRNA Delivery
Perche, F., Biswas, S., Wang, T., Zhu, L., & Torchilin, V. P. (2014) · Angewandte Chemie · doi:10.1002/ange.201308368 · Cited by 64
The Hypoxia-inducible Factor Renders Cancer Cells More Sensitive to Vitamin C-induced Toxicity
Tian, W., Wang, Y., Xu, Y., Guo, X., Wang, B., Sun, L., Liu, L., Cui, F., Zhuang, Q., Bao, X., et al. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.538157 · Cited by 59
“Nevertheless, hypoxia is a frequent event in most cancers, and it is known to induce drug resistance in tumors, which is in part mediated by HIF (61).”
BackgroundGong, Y. Q., Ding, P., Ning, X. H., Yang, X., Li, X. S., Zhou, L. Q., & Guo, Y. L. (2016) · Oncology Letters · doi:10.3892/ol.2016.5237 · Cited by 60
Simultaneous photoacoustic imaging of intravascular and tissue oxygenation
Chen, M., Knox, H. J., Tang, Y., Liu, W., Nie, L., Chan, J., & Yao, J. (2019) · Optics Letters · doi:10.1364/ol.44.003773 · Cited by 59
Extracellular Vesicles Are Key Regulators of Tumor Neovasculature
Kuriyama, N., Yoshioka, Y., Kikuchi, S., Azuma, N., & Ochiya, T. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.611039 · Cited by 60
Liu, J., Prentice, A. W., Clarkson, G. J., Woolley, J. M., Stavros, V. G., Paterson, M. J., & Sadler, P. J. (2023) · Advanced Materials · doi:10.1002/adma.202210363 · Cited by 60
Carbon Ions for Hypoxic Tumors: Are We Making the Most of Them?
Sokol, O., & Durante, M. (2023) · Cancers · doi:10.3390/cancers15184494 · Cited by 58
Mn( iii )-mediated carbon-centered radicals generate an enhanced immunotherapeutic effect
Li, J., Hu, B., Chen, Z., Li, J., Jin, W., Wang, Y., Wan, Y., Lv, Y., Pei, Y., Liu, H., et al. (2023) · Chemical Science · doi:10.1039/d3sc03635a · Cited by 59
Mendoza, E. N., Ciriolo, M. R., & Ciccarone, F. (2025) · Antioxidants · doi:10.3390/antiox14010094 · Cited by 73
Dynamic investigation of hypoxia-induced L-lactylation
Gao, J., Liu, R., Huang, K., Li, Z., Sheng, X., Chakraborty, K., Han, C., Zhang, D., Becker, L., & Zhao, Y. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2404899122 · Cited by 77
Chien, W., Lee, D. H., Zheng, Y., Wuensche, P., Alvarez, R., Wen, D. L., Aribi, A. M., Thean, S. M., Doan, N., SAID, J. W., et al. (2013) · Molecular Carcinogenesis · doi:10.1002/mc.22024 · Cited by 59
Carrer, A., Moimas, S., Zacchigna, S., Pattarini, L., Zentilin, L., Ruozi, G., Mano, M., Sinigaglia, M., Maione, F., Serini, G., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0762 · Cited by 67
Cancer-derived extracellular vesicles: the ‘soil conditioner’ in breast cancer metastasis?
Chin, A. R., & Wang, S. E. (2016) · Cancer and Metastasis Reviews · doi:10.1007/s10555-016-9639-8 · Cited by 64
Luo, G., Luo, W., Sun, X., Lin, J., Wang, M., Zhang, Y., Luo, W., & Zhang, Y. (2017) · Molecular Medicine Reports · doi:10.3892/mmr.2016.5971 · Cited by 59
RetractedLeptin signaling and cancer chemoresistance: Perspectives
Candelaria, P. V., Rampoldi, A., Harbuzariu, A., & Gonzalez-Perez, R. R. (2017) · World Journal of Clinical Oncology · doi:10.5306/wjco.v8.i2.106 · Cited by 69
Guo, D., Xu, S., Wang, N., Jiang, H., Huang, Y., Jin, X., Bai, X., Zhang, C., & Zhu, X. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.08.032 · Cited by 60
Hibernating astronauts—science or fiction?
Choukèr, A., Bereiter‐Hahn, J., Singer, D., & Heldmaier, G. (2018) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-018-2244-7 · Cited by 59
Xu, X., Gong, X., Wang, Y., Li, J., Wang, H., Wang, J., Sha, X., Li, Y., & Zhang, Z. (2020) · Advanced Therapeutics · doi:10.1002/adtp.201900181 · Cited by 60
Mamnoon, B., Feng, L., Froberg, J., Choi, Y., Sathish, V., & Mallik, S. (2020) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c00754 · Cited by 61
Yang, B., Dai, Z., Zhang, G., Hu, Z., Yao, X., Wang, S., Liu, Q., & Zheng, X. (2020) · Advanced Healthcare Materials · doi:10.1002/adhm.201901634 · Cited by 59
Platinum nanoplatforms: classic catalysts claiming a prominent role in cancer therapy
García-Peiro, J. I., Bonet‐Aleta, J., Santamaría, J., & Hueso, J. L. (2022) · Chemical Society Reviews · doi:10.1039/d2cs00518b · Cited by 61
Saggar, J. K., & Tannock, I. F. (2014) · International Journal of Cancer · doi:10.1002/ijc.28595 · Cited by 58
Vessel calibre—a potential MRI biomarker of tumour response in clinical trials
Emblem, K. E., Farrar, C. T., Gerstner, E. R., Batchelor, T. T., Borra, R. J. H., Rosen, B. R., Sorensen, A. G., & Jain, R. K. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.126 · Cited by 59
Chowdhury, G., Sarkar, U., Pullen, S. M., Wilson, W. R., Rajapakse, A., Fuchs-Knotts, T., & Gates, K. S. (2011) · Chemical Research in Toxicology · doi:10.1021/tx2004213 · Cited by 63
Self-citationZhi, X., Tao, J., Xie, K.-L., Zhu, Y., Li, Z., Tang, J., Wang, W., Xu, H., Zhang, J., & Xu, Z. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.12.021 · Cited by 58
Hypoxia After Liver Surgery Imposes an Aggressive Cancer Stem Cell Phenotype on Residual Tumor Cells
Govaert, K. M., Emmink, B. L., Nijkamp, M. W., Cheung, Z. J., Steller, E. J. A., Fatrai, S., de Bruijn, M. T., Kranenburg, O., & Borel Rinkes, I. H. M. (2014) · Annals of Surgery · doi:10.1097/sla.0b013e318295c160 · Cited by 58
Oxygen-Enhanced MRI Is a Major Advance in Tumor Hypoxia Imaging
Dewhirst, M. W., & Birer, S. R. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2818 · Cited by 68
Lee, J., Oh, E., Yoon, H., Kim, C. W., Han, Y., Song, J., Jang, H., Park, H. J., & Kim, C. (2017) · Nanoscale · doi:10.1039/c7nr00808b · Cited by 58
Jamieson, S. M. F., Tsai, P., Kondratyev, M. K., Budhani, P., Liu, A. J., Senzer, N. N., Chiorean, E. G., Jalal, S. I., Nemunaitis, J. J., Kee, D., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.122204 · Cited by 61
Self-citationGebremedhin, K. H., Li, Y., Yao, Q., Xiao, M. W., Gao, F., Fan, J., Du, J., Long, S., & Peng, X. (2018) · Journal of Materials Chemistry B · doi:10.1039/c8tb02635a · Cited by 58
Organic/inorganic nanohybrids rejuvenate photodynamic cancer therapy
Liang, C., Zhang, X., Wang, Z., Wang, W., Yang, M., & Dong, X. (2020) · Journal of Materials Chemistry B · doi:10.1039/d0tb00098a · Cited by 58
Li, Y., Liu, J., Wang, Z., Jin, J., Liu, Y., Chen, C., & Tang, Z. (2020) · Advanced Materials · doi:10.1002/adma.201907718 · Cited by 59
Li, Y., Liang, N., Qin, Y., Ma, D., Huang, C., Liu, L., & Li, S. (2016) · Tumor Biology · doi:10.1007/s13277-016-5458-3 · Cited by 57
RetractedmiRNAs as radio‐response biomarkers for breast cancer stem cells
Griñán‐Lisón, C., Olivares‐Urbano, M. A., Jiménez, G., López‐Ruiz, E., del Val, C., Morata‐Tarifa, C., Entrena, J. M., Ramírez, A. R. G., Boulaiz, H., Herrera, M. Z., et al. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12635 · Cited by 57
The therapeutic landscape of hepatocellular carcinoma
Gallage, S., Beccaria, M. G., Szydlowska, M., Rahbari, M., Mohr, R. U., Tacke, F., & Heikenwälder, M. F. (2021) · Med · doi:10.1016/j.medj.2021.03.002 · Cited by 64
Hypoxia signaling: Challenges and opportunities for cancer therapy
Ivan, M., Fishel, M. L., Tudoran, O. M., Pollok, K. E., Wu, X., & Smith, P. J. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.10.002 · Cited by 62
Small Two-Photon Organic Fluorogenic Probes: Sensing and Bioimaging of Cancer Relevant Biomarkers
Singh, A. K., Nair, A. V., & Singh, N. D. P. (2021) · Analytical Chemistry · doi:10.1021/acs.analchem.1c04306 · Cited by 57
Nitroaromatic Hypoxia-Activated Prodrugs for Cancer Therapy
Denny, W. A. (2022) · Pharmaceuticals · doi:10.3390/ph15020187 · Cited by 57
Stimuli-responsive nanoformulations for CRISPR-Cas9 genome editing
Fang, T., Cao, X., Ibnat, M., & Chen, G. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01570-y · Cited by 65
Recent progress in the development of singlet oxygen carriers for enhanced photodynamic therapy
Guo, L., Wu, M., Xu, Y., Wang, Q., Liu, J., Zhou, X., Ji, H., Tang, Q., Gu, X., Liu, S., et al. (2022) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2022.214979 · Cited by 57
New ways to image and target tumour hypoxia and its molecular responses
Dubois, L. J., Niemans, R., van Kuijk, S. J. A., Panth, K. M., Parvathaneni, N.-K., Peeters, S. G. J. A., Zegers, C. M. L., Rekers, N. H., van Gisbergen, M. W., Biemans, R., et al. (2015) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2015.08.022 · Cited by 60
Metadata
- Authors
- Wilson, W. R., & Hay, M. P.
- Affiliations
- University of Auckland (NZ)
- Corresponding author
- Wilson, William R.
- Venue
- Nature Reviews Cancer
- Published
- 2011-05-24
- Volume
- 11
- Issue
- 6
- Pages
- 393-410
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2024903578
- Cited by
- 3,172
- References
- 190
- Citations by year
- 2026: 109 · 2025: 165 · 2024: 196 · 2023: 206 · 2022: 268 · 2021: 298 · 2020: 319 · 2019: 238 · 2018: 274 · 2017: 238 · 2016: 223 · 2015: 188 · 2014: 164 · 2013: 156 · 2012: 102
- FWCI
- 10.38
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- ResearchSpace (University of Auckland) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity
- Keywords
- tumor hypoxia, cancer therapy, bioreductive prodrugs, chemoresistance, radioresistance (biology), angiogenesis, metastasis, cancer metabolism, genomic instability, patient stratification
- MeSH terms
- Antineoplastic Agents, Humans, Neoplasms, Prodrugs, Prognosis, Biomarkers, Tumor, Cell Hypoxia, Reactive Oxygen Species, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.